Small bowel metastasis from malignant tumors is generally rare and underreported. Numerous cases might be overlooked. Direct spread is more frequent and comes from colon, ovary, stomach, and uterus. Less commonly, hematogenous distant metastasis from melanoma, lung, and breast is encountered. Melanoma represents the most frequent primary source, while uterus is a less common source. In this report, we present a case of small bowel metastatic tumor from uterus presenting with profound anemia and impending obstruction.

Endometrial cancer is the fourth most common cancer in females and is the most prevalent gynecological malignancy. The majority of cases are diagnosed at an early stage with the tumor confined to the uterus at the time of hysterectomy, which provides an excellent overall prognosis and a 5-year survival rate exceeding 70%. Two histological types of endometrial cancer have been recognized as biologically distinct disease entities; type I and type II. Type I comprises endometroid carcinoma and its variants; type II consists of serous carcinoma, clear cell carcinoma, and carcinosarcoma. Endometroid carcinoma (type I) accounts for the majority of cases [1]. However, uterine serous carcinoma has a higher tendency for lymphovascular invasion in addition to intraperitoneal and extra-abdominal spread.

Typical sites of metastasis of endometrial carcinoma are pelvic and para-aortic lymph nodes, vagina, peritoneum, and lungs [2]. Atypical sites include bones, brain, abdominal wall, muscle, and intra-abdominal organs. The liver (7%) is the most commonly involved intra-abdominal organ followed by the adrenal glands and spleen (1%). Metastasis from endometrial cancer to small bowel is very rare [3].

In this report, we highlight an unusual site of metastasis of an endometrial adenocarcinoma to the small intestine.

An 88-year-old female patient was admitted to the Medical Department of Rashid Hospital, Dubai (UAE) due to progressive drop in hemoglobin. The patient had a past surgical history of a total abdominal hysterectomy for endometrial carcinoma, which was performed 5 months prior to presentation. Patient hemoglobin dropped from 10.5 to 8 g/dL over the past 2 months, occult blood stool test was positive, and she has received multiple blood transfusions. Upper and lower gastrointestinal (GI) endoscopy were requested and scheduled for her but were not done as the patient started complaining of abdominal pain that was not associated with nausea, vomiting, or constipation. On examination, the patient was conscious and alert. Her vitals were as follows: BP 115/60 mm Hg, pulse 60 beats/min, RR: 18, afebrile; her abdomen was not distended, with tenderness and rebound tenderness in the left upper quadrant and positive bowel sounds. Rectal examination was done, which was unremarkable with no bleeding or melena.

Her labs were as follows: WBC: 4.0 × 103/μL, platelet count: 97 × 109/L, creatinine: 0.7 mg/dL, prothrombin time: 23.3 s; the rest of the lab investigations were within normal limits. CT of the abdomen and pelvis revealed a large necrotic mass lesion (6.5 × 5.6 cm) in relation to the mid-jejunal loops with mural wall thickening and a localized luminal narrowing with a large mesenteric exophytic component associated with significantly enlarged localized mesenteric nodes (Fig. 1). Exploratory laparotomy revealed a hard exophytic tumor of 10 cm in size, about 90 cm from the DJ flexure with omental and fibrinous adhesions to nearby bowel (Fig. 1). Resection of the affected segment and side-to-side anastomosis were performed. Histopathology revealed metastatic poorly differentiated adenocarcinoma involving the small bowel. The immunohistochemistry performed on the small bowel tumor showed positivity for CKAE1/AE3, ER, P53, and focally positive for PR. Chromogranin and CD56 immunohistochemical markers were negative. Morphology and immunohistochemical profile was consistent with metastatic adenocarcinoma of the small bowel in keeping with uterine primary (Fig. 2a–d).

Fig. 1.

Resected part of bowel showing hard exophytic tumor of 10 cm in size, about 90 cm from the DJ flexure.

Fig. 1.

Resected part of bowel showing hard exophytic tumor of 10 cm in size, about 90 cm from the DJ flexure.

Close modal
Fig. 2.

Histopathology findings. a S17-254-10×: 10× is the magnification. The picture shows a low-power view of the tumor showing tumor arranged in nests and broad trabeculae. b S17-254-40× (three pictures): 40× is the high-power magnification. The picture shows sheets of tumor cells showing high N/C ratio with pleomorphic hyperchromatic nuclei containing prominent nucleoli. Brisk mitosis is identified with areas of desmoplastic stromal response. c S17-254-cytokeratin: epithelial immunostain positivity confirming epithelial nature of malignancy. d S17-254-estrogen receptor and P53: both immunostains show nuclear positivity in tumor cells.

Fig. 2.

Histopathology findings. a S17-254-10×: 10× is the magnification. The picture shows a low-power view of the tumor showing tumor arranged in nests and broad trabeculae. b S17-254-40× (three pictures): 40× is the high-power magnification. The picture shows sheets of tumor cells showing high N/C ratio with pleomorphic hyperchromatic nuclei containing prominent nucleoli. Brisk mitosis is identified with areas of desmoplastic stromal response. c S17-254-cytokeratin: epithelial immunostain positivity confirming epithelial nature of malignancy. d S17-254-estrogen receptor and P53: both immunostains show nuclear positivity in tumor cells.

Close modal

In spite of the fact that the small intestine constitutes the majority of the total mucosal surface of the GI tract, less than 2% of malignancies of the GI tract arise from the small bowel [4]. Adenocarcinoma is the most prevalent malignancy of the small intestine. However, metastatic involvement of the intestine is more common than primary small intestinal neoplasia. Extra-intestinal neoplasms can metastasize to the small bowel through hematogenous spread (breast, lung, and melanoma), direct invasion, or intraperitoneal seeding (colon, ovary, stomach, and uterus) [5]. Melanoma has the highest tendency to metastasize to the small intestine. However, small bowel metastasis from uterine cancer is a less common entity compared to metastasis from melanomas.

A number of mechanisms are believed to be the reason for the low rates of metastasis to the small intestine, which includes: (1) intensive lymphoid tissue and abundant secretions of IgA in the submucosal and mucosal layers; (2) high turnover rate of the small intestinal mucosa, which impedes tumorigenesis [6, 7].

Small-bowel cancer is typically asymptomatic in its early stages, but more than 90% of patients eventually develop symptoms as the disease progresses. This unfortunately reflects advanced disease [8].

For that reason, small bowel secondary tumors are often missed at initial presentation and the accurate diagnosis is delayed due to the nonspecific nature of symptoms. A significant delay between the onset of symptoms and diagnosis often occurs, averaging few months. It has been reported that the mean duration from the onset of the initial complaint to diagnosis is 7 months. This is in view of the fact that they generally progress in a surreptitious manner with nonspecific complaints, for instance, intermittent abdominal pain, anemia, or bleeding [9, 10].

Generally, nausea, vomiting, and intestinal obstruction are common presenting symptoms. Half of these patients undergo emergency surgery for intestinal obstruction as in this case. Abdominal pain and weight loss complicate the clinical presentation, while GI bleeding is less common [11]. There are very few published series on small bowel secondary neoplasms, which might be due to underreporting as cases might be overlooked due to varying presentation of the individual histologic subtypes [12, 13]. However, it does appear that adenocarcinomas are more frequently associated with pain and obstruction when compared to sarcomas and carcinoids. Sarcomas (GIST) present more commonly with acute GI bleeding [14].

Small bowel metastasis is a rare entity. Metastases from the uterus are less common compared to melanoma and generally underreported. Due to bizarre symptoms, a high index of suspicion and screening of patients at risk is to be recommended to avoid delaying the diagnosis.

The authors are greatly indebted to Mr. B.B., Specialist Medical Training Section/DHA Library, Medical Education and Research Department for the great effort and help for preparing the manuscript.

Signed consent was taken from the guardian.

The authors have nothing to disclose

No funding was required.

The authors have equally contributed in collecting data and preparation of the manuscript.

1.
Cheung
DY
,
Choi
MG
.
Current advance in small bowel tumors
.
Clin Endosc
.
2011
Sep
;
44
(
1
):
13
21
.
[PubMed]
2234-2400
2.
Xynopoulos
D
,
Mihas
AA
,
Paraskevas
E
,
Dimitroulopoulos
D
,
Heuman
DM
.
Small bowel tumors
.
Ann Gastroenterol
.
2002
.1108-7471
3.
Sugimoto
T
,
Mike
M
,
Abe
M
,
Kano
N
.
Small bowel metastasis of uterine cervical adenocarcinoma
.
BMJ Case Rep
.
2013
Aug
;
2013
aug26 1
:
007896
.
[PubMed]
1757-790X
4.
Yu
X
,
Wang
Z
,
Zhang
Z
,
Liu
Y
,
Huang
J
.
Postoperation of cervical cancer with intestine metastasis: a case report and literature review
.
World J Surg Oncol
.
2016
Jan
;
14
(
1
):
2
.
[PubMed]
1477-7819
5.
Blazer
DG
 3rd
,
Ramirez
PT
,
Wang
H
,
Fleming
JB
.
Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas
.
JOP
.
2008
Jan
;
9
(
1
):
56
60
.
[PubMed]
1590-8577
6.
Roma
AA
,
Rybicki
LA
,
Barbuto
D
,
Euscher
E
,
Djordjevic
B
,
Frauenhoffer
E
, et al
Risk factor analysis of recurrence in low-grade endometrial adenocarcinoma
.
Hum Pathol
.
2015
Oct
;
46
(
10
):
1529
39
.
[PubMed]
0046-8177
7.
Kurra
V
,
Krajewski
KM
,
Jagannathan
J
,
Giardino
A
,
Berlin
S
,
Ramaiya
N
.
Typical and atypical metastatic sites of recurrent endometrial carcinoma
.
Cancer Imaging
.
2013
Mar
;
13
(
1
):
113
22
.
[PubMed]
1740-5025
8.
Awrich
AE
,
Irish
CE
,
Vetto
RM
,
Fletcher
WS
.
A twenty-five year experience with primary malignant tumors of the small intestine
.
Surg Gynecol Obstet
.
1980
Jul
;
151
(
1
):
9
14
.
[PubMed]
0039-6087
9.
Zollinger
RM
 Jr
,
Sternfeld
WC
,
Schreiber
H
.
Primary neoplasms of the small intestine
.
Am J Surg
.
1986
Jun
;
151
(
6
):
654
8
.
[PubMed]
0002-9610
10.
Ouriel
K
,
Adams
JT
.
Adenocarcinoma of the small intestine
.
Am J Surg
.
1984
Jan
;
147
(
1
):
66
71
.
[PubMed]
0002-9610
11.
Ebert
PA
,
Zuidema
GD
.
Primary tumors of the small intestine
.
Arch Surg
.
1965
Sep
;
91
(
3
):
452
5
.
[PubMed]
0004-0010
12.
Bauer
RL
,
Palmer
ML
,
Bauer
AM
,
Nava
HR
,
Douglass
HO
 Jr
.
Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis
.
Ann Surg Oncol
.
1994
May
;
1
(
3
):
183
8
.
[PubMed]
1068-9265
13.
Garcia
JM
,
Sanchez
FB
,
Aguilar
J
,
Parrilla
PP
.
Primary small bowel malignant tumors.
European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
1994
;20(6):630-634
14.
Adler
SN
,
Lyon
DT
,
Sullivan
PD
.
Adenocarcinoma of the small bowel. Clinical features, similarity to regional enteritis, and analysis of 338 documented cases
.
Am J Gastroenterol
.
1982
May
;
77
(
5
):
326
30
.
[PubMed]
0002-9270
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.